Do All Stage IA Pancreatic Cancer Patients Need Adjuvant Chemotherapy?

Area of Science:

• Oncology
• Surgical Oncology
• Clinical Research

Background:

• National guidelines suggest adjuvant chemotherapy (AC) for all pancreatic ductal adenocarcinoma (PDAC) stages post-resection.
• The benefit of AC in Stage IA PDAC remains uncertain, necessitating identification of patients who might not require it.

Purpose of the Study:

• To identify a specific subgroup of Stage IA PDAC patients who could potentially forgo AC.
• To determine if omitting AC in select Stage IA PDAC patients is a safe and viable option.

Main Methods:

• Utilized the National Cancer Database (NCDB) to identify Stage IA PDAC patients diagnosed between 2010 and 2021.
• Compared outcomes between patients who received AC and those who did not.
• Performed multivariable analysis to pinpoint risk factors impacting overall survival (OS).

Main Results:

• Analysis included 1421 patients; nine factors were linked to worse OS, including advanced age, lower income, Medicare insurance, higher tumor grade, lymphovascular invasion (LVI), positive surgical margins, fewer than 12 examined lymph nodes, and extended hospital stay.
• A negative correlation was observed between OS and an increasing number of identified risk factors.
• AC demonstrated improved OS in patients with three or more risk factors (54 months increase for three factors, 11.4 months for four or more).
• Patients with fewer than three risk factors showed no significant OS improvement with AC.

Conclusions:

• Adjuvant chemotherapy (AC) does not appear to benefit Stage IA PDAC patients presenting with fewer than three identified risk factors.
• It may be considered safe to omit AC in Stage IA PDAC patients with fewer than three risk factors, allowing for personalized treatment strategies.